YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Cognizant Technology Solutions (NasdaqGS: CTSH) announced multi-year AI-focused partnerships with Gilead Sciences and SITA. The Gilead agreement targets AI-enabled DevOps and finance transformation programs using Cognizant's cloud and auto…
Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–b…
Abbott Laboratories (NYSE:ABT) is a business that is not showcasing any rapid growth trends. However, what makes it an attractive investment prospect is the company's consistent track record of incremental dividends, with 411 consecutive q…
[Wall Street New York stock exchange stock market] alexsl U.S. equities traded to the downside on Wednesday as investors looked forward to the release of the Federal Reserve's latest meeting minutes later in the day. The blue-chip Dow (DJI…
Entera Bio Ltd. Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:…
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:…
Nurix Therapeutics, Inc. Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 0…
In the latest close session, Gilead Sciences (GILD) was down 1.87% at $144.74. The stock's change was less than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%…
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out. Continue Reading
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, s…
Gilead Sciences (GILD) ended the recent trading session at $149.45, demonstrating a -1.21% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow lost 0.86%, while the tech-h…
[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and pr…
Company Logo The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding cl…
Sware gains 35 years of pharma technology leadership as life sciences organizations modernize validation for the AI era BOSTON, September 29, 2026--(BUSINESS WIRE)--Sware, Inc., the company behind the Res_Q, the AI-powered validation platf…
Check out the companies making the biggest moves premarket: Fair Isaac — Shares plunged 18% after Federal Housing Finance Agency director Bill Pulte introduced changes to mortgage pricing. "We are Simplifying Mortgage Pricing following fee…
Company Logo AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities. Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Molecu…
On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Cov…
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don't make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around r…
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that i…
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead's momentum is being driven primarily by its HIV portfolio, where established medicines and ne…
Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that alre…
Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dom…
Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an H…
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johns…
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and b…
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) an…
DENVER, September 24, 2026--(BUSINESS WIRE)--The Barron's 400 ETF (NYSE Arca: BFOR, the "Fund"), a smart beta exchange-traded fund, has completed its semi-annual rebalance following the reconstitution and equal weighting of its underlying…
In the latest trading session, Gilead Sciences (GILD) closed at $152.67, marking a +1.4% move from the previous day. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.45%. The HIV and…
The Federal Reserve's decision last week to raise interest rates for the first time since 2023 has stirred fears that the economy is moving into the later stages of the business cycle. Morgan Stanley sees something different: a "classic" m…
Reflecting On Therapeutics Stocks' Q2 Earnings: AbbVie (NYSE:ABBV) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at AbbVie (NYSE:ABBV) and its peers. Over the n…
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to mi…
Bristol Myers Squibb BMY and Gilead Sciences, Inc. GILD are two leading biotech players with diversified portfolios and a strong global presence. Bristol Myers Squibb has built a robust portfolio comprising drugs for oncology, hematology,…
This article first appeared on GuruFocus. Novo Nordisk A/S (NYSE:NVO) shares fell 5.96% in Copenhagen trading, as the Danish drugmaker used its London Capital Markets Day to lay out 2030 strategic ambitions, the first full reset under new…
Key Points Interested in Lakefront Biotherapeutics American Depositary Shares? Here are five stocks we like better. Lakefront plans to start registrational trials for gamgertamig in ITP and AIHA in 2027, with additional autoimmune basket s…
Morgan Stanley met privately with Gilead Sciences (GILD) leadership at its 2026 Global Healthcare Conference this month, and the feedback strengthened the bank's positive view on the stock. Morgan Stanley's biopharma team hosted a meeting…